Malformations, genetic abnormalities, and wilms tumor
- 23 August 2013
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 61 (1), 140-144
- https://doi.org/10.1002/pbc.24709
Abstract
Background Wilms Tumor (WT) can occur in association with tumor predisposition syndromes and/or with clinical malformations. These associations have not been fully characterized at a clinical and molecular genetic level. This study aims to describe clinical malformations, genetic abnormalities, and tumor predisposition syndromes in patients with WT and to propose guidelines regarding indications for clinical and molecular genetic explorations. Procedure This retrospective study analyzed clinical abnormalities and predisposition syndromes among 295 patients treated for WT between 1986 and 2009 in a single pediatric oncological center. Results Clinically identified malformations and predisposition syndromes were observed in 52/295 patients (17.6%). Genetically proven tumor predisposition syndromes (n = 14) frequently observed were syndromes associated with alterations of the chromosome WT1 region such as WAGR (n = 6) and Denys–Drash syndromes (n = 3), syndromes associated with alterations of the WT2 region (Beckwith–Wiedeman syndrome, n = 3), and Fanconi anemia (n = 2). Hemihypertrophy and genito‐urinary malformations (n = 12 and n = 16, respectively) were the most frequently identified malformations. Other different syndromes or malformations (n = 10) were less frequent. Median age of WT diagnosis was significantly earlier for children with malformations than those without (27 months vs. 37 months, P = 0.0009). There was no significant difference in terms of 5‐year EFS and OS between WT patients without or with malformations. Conclusions The frequency of malformations observed in patients with WT underline the need of genetic counseling and molecular genetic explorations for a better follow‐up of these patients, with a frequently good outcome. A decisional tree, based on clinical observations of patients with WT, is proposed to guide clinicians for further molecular genetic explorations. Pediatr Blood Cancer 2014;61:140–144.Keywords
This publication has 24 references indexed in Scilit:
- Addition of H19 ‘Loss of Methylation Testing’ for Beckwith-Wiedemann Syndrome (BWS) Increases the Diagnostic YieldThe Journal of Molecular Diagnostics, 2010
- Congenital anomaly and childhood cancer: A population‐based, record linkage studyPediatric Blood & Cancer, 2008
- Congenital abnormalities and clinical features associated with Wilms’ tumour: A comprehensive study from a centre serving a large populationEuropean Journal of Cancer, 2007
- Syndromes and constitutional chromosomal abnormalities associated with Wilms tumourJournal of Medical Genetics, 2006
- Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumourJournal of Medical Genetics, 2005
- Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trialThe Lancet, 2004
- Evidence for a familial Wilms' tumour gene (FWT1) on chromosome 17q12–q21Nature Genetics, 1996
- Wilms' tumor in the Li-Fraumeni cancer family syndromeCancer Genetics and Cytogenetics, 1993
- Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndromeCell, 1991
- Complete and incomplete forms of Beckwith-Wiedemann syndrome: Their oncogenic potentialThe Journal of Pediatrics, 1980